A new stimulator of hematopoietic function is looking for investors
Currently, there are several similar drugs on the market. In comparison with Leukostim, the specific activity of Neutrostim is higher, and unlike "Neupogen" it does not affect red blood cells. In addition, there is reason to believe that the new drug will be cheaper than analogues. The volume of necessary investments is $5 million.
18.02.2009